Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.53 |
| ▸ | CDK4 | P11802 | 8/20 | 0.51 |
| ▸ | CCND1 | P24385 | 7/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.43 |
| ▸ | CDK2 | P24941 | 5/20 | 0.43 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.43 |
| ▸ | CCND3 | P30281 | 3/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4244130 | 0.99 | CHRNB2 (0.51) | CHRNB2CHRNA4CDK4CCND1ABL1 | |
| SCHEMBL28562923 | 0.95 | CHRNB2 (0.57) | CHRNB2CHRNA4CDK4CCND1CCNA2 | |
| Trifluoroacetic Acid SCHEMBL29544383 | 0.89 | AOC3 (0.44) | CHRNB2CHRNA4CDK4CCND1ABL1 | |
| Trifluoroacetic Acid SCHEMBL28705254 | 0.89 | AOC3 (0.44) | CHRNB2CHRNA4CDK4CCND1ABL1 | |
| Trifluoroacetic Acid SCHEMBL18453319 | 0.89 | AOC3 (0.44) | CHRNB2CHRNA4CDK4CCND1ABL1 | |
| Trifluoroacetic Acid SCHEMBL18453329 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4CDK4CCND1AOC3 | |
| SCHEMBL18453953 | 0.85 | MAPT (0.44) | CHRNB2CHRNA4CDK4CCND1ABL1 | |
| SCHEMBL24483273 | 0.85 | CHRNB2 (0.49) | CHRNB2CHRNA4CDK4CCND1ABL1 | |
| SCHEMBL28717895 | 0.82 | POLB (0.47) | CDK4CCND1CCNA2CDK2CCND3 | |
| SCHEMBL28937063 | 0.82 | FLT3 (0.47) | CDK4CCND1ABL1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850244-B2 | Method for preparing Palbociclib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-12-26 | — | — | US | claimed |
| US-20170247379-A1 | METHOD FOR PREPARING PALBOCICLIB | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-08-31 | — | — | US | claimed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-114269742-A | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amines as therapeutic agents | 常州千红生化制药股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| CN-107936029-B | Method for synthesizing Ribociclib | 南京奇可药业有限公司 | 2020-06-30 | — | — | CN | disclosed |
| US-10005726-B2 | Ribociclib intermediate and preparation method therefor | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-06-26 | — | — | US | disclosed |
| US-10005726-B2 | Ribociclib intermediate and preparation method therefor | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-06-26 | — | — | US | disclosed |
| US-20180093950-A1 | RIBOCICLIB INTERMEDIATE AND PREPARATION METHOD THEREFOR | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-04-05 | — | — | US | disclosed |
| US-20180093950-A1 | RIBOCICLIB INTERMEDIATE AND PREPARATION METHOD THEREFOR | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-04-05 | — | — | US | disclosed |
| US-9850244-B2 | Method for preparing Palbociclib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-12-26 | — | — | US | disclosed |
| US-9850244-B2 | Method for preparing Palbociclib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-12-26 | — | — | US | disclosed |
| US-20170247379-A1 | METHOD FOR PREPARING PALBOCICLIB | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247379-A1 | METHOD FOR PREPARING PALBOCICLIB | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| CN-105906622-A | Preparation method of palbociclib for treating breast cancer | 青岛云天生物技术有限公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| CN-101163694-A | Imidaz0l0-5-yl-2-anil0-pyrimidines as agents for the inhibition of cell proliferation | ASTRAZENECA AB ASTRAZENECA UK (SE) | 2008-04-16 | — | — | CN | disclosed |
| EP-1869016-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006095159-A1 | (IMIDAZOLO-5-YL)-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005726-B2 | Ribociclib intermediate and preparation method therefor | WEE1, WEE2, CPSF7 | CHRNB2 4337/4885CHRNA4 3884/4885CDK4 53/4885 |
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | CHRNB2 4788/4885CHRNA4 4770/4885CDK4 30/4885 |
| US-20170247379-A1 | METHOD FOR PREPARING PALBOCICLIB | CHUK, TPMT, ME1 | CHRNB2 4662/4885CHRNA4 4108/4885CDK4 6/4885 |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDKL2 | CHRNB2 3507/4885CHRNA4 3087/4885CDK4 1/4885 |
| US-20180093950-A1 | RIBOCICLIB INTERMEDIATE AND PREPARATION METHOD THEREFOR | WEE1, WEE2, CPSF7 | CHRNB2 4337/4885CHRNA4 3884/4885CDK4 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.